Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug...
Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)(PRWeb October 26, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13042760.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 26, 2015 Category: Pharmaceuticals Source Type: news
Do We Need a New Pill Drill?
Commercials that get into our kids heads drive us crazy. When we see them salivating over enticing ads designed to make them pine for every last morsel of candy, new gimmick or any unhealthy vice, we are outraged. And we should be. It's pretty despicable companies do this. As adults, we are also of great interest to marketers, but the version of "candy" being shoved down our throats -- almost literally -- are prescription meds. The United States, along with New Zealand are the only two countries across the world that allows Direct-to-Consumer (DTC) pharmaceutical advertisements. We turn on our television and are bombar...
Source: Healthy Living - The Huffington Post - October 25, 2015 Category: Consumer Health News Source Type: news
Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia
Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2015 Category: Pharmaceuticals Source Type: news
Aristada (Aripiprazole Lauroxil Extended-release Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 14, 2015 Category: Drugs & Pharmacology Source Type: news
Extended-Release Schizophrenia Drug Approved (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The FDA has approved extended-release aripiprazole lauroxil (marketed as … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 7, 2015 Category: Primary Care Source Type: news
FDA Clears Long-Lasting Drug for Schizophrenia
The FDA has approved a version of the antipsychotic drug aripiprazole that adults with schizophrenia can take every 4-6 weeks. WebMD has the details. (Source: WebMD Health)
Source: WebMD Health - October 6, 2015 Category: Consumer Health News Source Type: news
FDA Approves Alkermes' Injectable Schizophrenia Drug
Alkermes' Aristada (aripiprazole lauroxil) extended release injection is approved to treat adults with schizophrenia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 6, 2015 Category: Pharmaceuticals Source Type: news
FDA Clears Long-Acting Aripiprazole for SchizophreniaFDA Clears Long-Acting Aripiprazole for Schizophrenia
The FDA has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
FDA approves new injectable drug to treat schizophrenia
On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 6, 2015 Category: American Health Source Type: news
Alkermes' schizophrenia drug Aristada gets FDA nod
(Reuters) - The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Alkermes's Aristada gets FDA approval to treat schizophrenia
Ireland-based Alkermes has received approval from the US Food and Drug Administration (FDA) for Aristada (aripiprazole lauroxil) extended-release injectable suspension to treat schizophrenia. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 5, 2015 Category: Pharmaceuticals Source Type: news
This Treatment May Help Depression in Older People
When a doctor prescribes aripiprazole (Abilify), an antipsychotic drug, for an older person already taking the antidepressant venlafaxine, that combination can help ease depression that doesn't get better with typical treatment, according to a new study. (Source: WebMD Health)
Source: WebMD Health - October 1, 2015 Category: Consumer Health News Source Type: news
Add-On Aripiprazole Helps Manage Treatment-Resistant Depression in Elders (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Adding the atypical antipsychotic aripiprazole (Abilify) to an antidepressant can help older adults with difficult-to-treat depression, a Lancet study finds. Over … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 28, 2015 Category: Primary Care Source Type: news
FDA to review Proteus ‘smart pill’ with Otuka’s Abilify anti-depressant
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said yesterday that the FDA will review a combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug.
The companies said the FDA accepted their new drug application for the drug-device combination, using the Proteus ingestible sensor and Otsuka’s aripiprazole drug in patients with serious mental illnesses such as major depressive disorder, bipolar disorder and schizophrenia. It’s the 1st time the federal safety watchdog has reviewed a drug-device combo designed to measure adherence.
The Proteus pill is design...
Source: Mass Device - September 11, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Otsuka Pharmaceutical Proteus Digital Health Source Type: news
Proteus, Otsuka submit first commercial drug with built-in sensor to FDA
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus’s ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval. “Today, patients suffering from severe mental […] (Source: mobihealthnews)
Source: mobihealthnews - September 10, 2015 Category: Information Technology Authors: Jonah Comstock Tags: Government/Regulation Pharma Uncategorized Abilify ingestible sensor Otsuka Pharmaceuticals Proteus Digital Health Proteus Digital Health feedback system Source Type: news
